HIV treatment bulletin

RSS Atom • ISSN 1472-4683 • Subscribe • About

2005

Next page

• Volume 6 Number 11/12 November/December 2005 Editorial - 13 December 2005

• 7th Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, 13-16 November 2005, Dublin, Ireland Conference reports - Conference index - Lipodystrophy Workshop (IWADRW) 7 Dublin 2005 - 13 December 2005

• Monitoring side effects in resource limited countries Conference reports - Side effects - Lipodystrophy Workshop (IWADRW) 7 Dublin 2005 - 13 December 2005

• Uridine supplement reverses thymidine-induced lipoatrophy Conference reports - Lipodystrophy and metabolic complications - Side effects - Lipodystrophy Workshop (IWADRW) 7 Dublin 2005 - 13 December 2005

• Pravastatin increases limb fat in HIV-positive patients with hypercholesterolaemia Conference reports - Lipodystrophy and metabolic complications - Side effects - Lipodystrophy Workshop (IWADRW) 7 Dublin 2005 - 13 December 2005

• Evidence that facial fat can return after switching from either d4T or AZT, to abacavir or tenofovir Conference reports - Lipodystrophy and metabolic complications - Side effects - Lipodystrophy Workshop (IWADRW) 7 Dublin 2005 - 13 December 2005

• Niacin has beneficial effect on lipids but no reduction in abdominal fat Conference reports - Lipodystrophy and metabolic complications - Side effects - Lipodystrophy Workshop (IWADRW) 7 Dublin 2005 - 13 December 2005

• Gluteal implants used to replace lost buttock fat Conference reports - Lipodystrophy and metabolic complications - Side effects - Lipodystrophy Workshop (IWADRW) 7 Dublin 2005 - 13 December 2005

• 10th European AIDS Conference, 17-20 November 2005, Dublin, Ireland Conference reports - Conference index - EACS 10 Dublin 2005 - 13 December 2005

• Pregnancy studies at EACS Conference reports - PMTCT and maternal health - EACS 10 Dublin 2005 - 13 December 2005

• Brazil’s deal with Abbott is challenged in courts Treatment access - 13 December 2005

• Named-patient access programme available in UK for new protease inhibitor darunavir (TMC114) Antiretrovirals - 13 December 2005

• Tibotec discontinues TMC125 study C227: phase III studies continue Antiretrovirals - 13 December 2005

• New Kaletra tablet formulation (meltrex) approved by FDA Antiretrovirals - 13 December 2005

• GSK closes Phase 3 studies of its CCR5 inhibitor aplaviroc and terminates development programme Antiretrovirals - 13 December 2005

• Schering discontinues Phase II studies of vicriviroc in treatment naive patients Antiretrovirals - 13 December 2005

• FDA issues approvable letter for Bioject needle-free injection device Antiretrovirals - 13 December 2005

• Cost effectiveness of resistance testing for treatment-naive patients Resistance - 13 December 2005

• Improved clinical outcome in 80% patients who modified an NNRTI or PI dose following therapeutic drug monitoring (TDM) Antiretrovirals - Treatment strategies - 13 December 2005

• US pregnancy guidelines updated Guidelines - PMTCT and maternal health - 13 December 2005

• European activists denounce pricing increases for HIV drugs as 'unbearable' Other news - 13 December 2005

• Guidelines for the use of antiretroviral agents in pediatric HIV infection On the web - 13 December 2005

• American Association For The Study of Liver Diseases (AASLD), November 11-15, 2005 San Francisco On the web - 13 December 2005

• Medscape articles and online papers On the web - 13 December 2005

• Community newsletters and journals On the web - 13 December 2005

• HIV inSite Knowledge Base On the web - 13 December 2005

• Amedeo HIV Medicine On the web - 13 December 2005

• Volume 6 Number 11/12 November/December 2005 PDF PDFs - 1 December 2005

• Volume 6 Number 10 October 2005 Editorial - 13 October 2005

• Further Reports from 3rd IAS Conference on AIDS Pathogenesis and Treatment, Rio de Janeiro, Brazil, 24-27 July 2005 Conference reports - Conference index - IAS 3 Rio de Janeiro 2005 - 13 October 2005

• Management of hepatitis C and B in HIV-coinfected individuals: an overview of studies presented at the 3rd IAS Conference Conference reports - Hepatitis coinfection - IAS 3 Rio de Janeiro 2005 - 13 October 2005

• Highlights of HIV drug resistance studies presented at the 3rd IAS Conference Conference reports - Resistance - IAS 3 Rio de Janeiro 2005 - 13 October 2005

• GSK stops trials of CCR5 entry inhibitor GW873140 in naive patients Antiretrovirals - 13 October 2005

• AZT comes off patent: generic versions approved for US market Antiretrovirals - 13 October 2005

• Depletion of latent HIV-1 reservoir with valproic acid: interesting data but not a cure Basic science and immunology - Treatment access - 13 October 2005

• Fatigue among HIV-positive patients in the era of highly active antiretroviral therapy Side effects - 13 October 2005

• Breast milk, HIV suppression and decreased mother to child transmission PMTCT and maternal health - 13 October 2005

• Single dose nevirapine infant prophylaxis to reduce mother to child transmission may have similar efficacy to maternal and infant doses PMTCT and maternal health - 13 October 2005

• Pharmacokinetics of nevirapine in HIV positive children receiving Thai fixed dose combination Paediatric care - 13 October 2005

• WHO – Patients for patient safety: call for participants Other news - 13 October 2005

• Does buprenorphine have a role in preventing HIV transmission and treating HIV-infected IDUs? Other news - 13 October 2005

• Medscape articles and online papers On the web - 13 October 2005

• Neurological complications of HIV infection On the web - 13 October 2005

• HIV inSite Knowledge Base On the web - 13 October 2005

• WHO list of essential medicines On the web - 13 October 2005

• Volume 6 Number 10 October 2005 PDF PDFs - 1 October 2005

• Volume 6 Number 9 September 2005 Editorial - 14 September 2005

• 3rd IAS Conference on HIV Pathogenesis and Treatment, 24-27 July 2005, Rio de Janeiro, Brasil Conference reports - Conference index - IAS 3 Rio de Janeiro 2005 - 14 September 2005

• Adult male circumcision reduces transmission rates over 18 months comparable to a vaccine with 65% efficacy Conference reports - Transmission and prevention - IAS 3 Rio de Janeiro 2005 - 14 September 2005

• Benefits of adding 4 or 7 days of AZT/3TC to single-dose nevirapine to prevent MTCT: further analysis from TOPS Conference reports - PMTCT and maternal health - IAS 3 Rio de Janeiro 2005 - 14 September 2005

• New drugs in pregnancy: atazanavir; T20 Conference reports - PMTCT and maternal health - IAS 3 Rio de Janeiro 2005 - 14 September 2005

• Lopinavir/r use in children less than two years old – promising results despite low plasma levels Conference reports - Paediatric care - IAS 3 Rio de Janeiro 2005 - 14 September 2005

• Favourable outcomes in children treated with HAART in the MSF programmes Conference reports - Paediatric care - IAS 3 Rio de Janeiro 2005 - 14 September 2005

• Encouraging results with cut up generic fixed dose combination tablets in Uganda Conference reports - Paediatric care - IAS 3 Rio de Janeiro 2005 - 14 September 2005

• Predictors of survival at three years follow up for HIV-infected children in Cote D'Ivoire Conference reports - Paediatric care - IAS 3 Rio de Janeiro 2005 - 14 September 2005

• Benefit of maintaining the M184V mutation with 3TC monotherapy: final 48-week results Antiretrovirals - Conference reports - IAS 3 Rio de Janeiro 2005 - 14 September 2005

• T20 (enfuvirtide) studies presented at Rio Conference reports - IAS 3 Rio de Janeiro 2005 - 14 September 2005

• Strategies for salvage therapy Antiretrovirals - Conference reports - IAS 3 Rio de Janeiro 2005 - 14 September 2005

• Antiviral activity of foscarnet in salvage patients Antiretrovirals - Conference reports - IAS 3 Rio de Janeiro 2005 - 14 September 2005

• Novel strategies with existing drugs Antiretrovirals - Conference reports - IAS 3 Rio de Janeiro 2005 - 14 September 2005

• Antiretroviral activity of new and novel agents Antiretrovirals - Conference reports - IAS 3 Rio de Janeiro 2005 - 14 September 2005

• Overview of pharmacology studies Conference reports - PK and drug interactions - IAS 3 Rio de Janeiro 2005 - 14 September 2005

• Incidence of TB infection despite HAART and treatment in coinfected patients Conference reports - TB coinfection - IAS 3 Rio de Janeiro 2005 - 14 September 2005

• Evaluation of ESAT-6 and CFP-10 as markers for response to TB treatment in HIV/TB coinfected patients Conference reports - TB coinfection - IAS 3 Rio de Janeiro 2005 - 14 September 2005

• Does WHO clinical stage reliably predict who should receive ARV treatment? Conference reports - Treatment access - IAS 3 Rio de Janeiro 2005 - 14 September 2005

• Continuous vs intermittent treatment with triple nuke combination of AZT/3TC/tenofovir in Africa: early results from DART study Conference reports - Treatment access - IAS 3 Rio de Janeiro 2005 - 14 September 2005

• Global Fund commitment to $175M annually in 2006, 2007 Treatment access - 14 September 2005

• UK treatment guidelines 2005 online Guidelines - 14 September 2005

• EMEA statement on metabolic and cardiovascular complications of antiretroviral therapy in HIV-infected patients Side effects - 13 September 2005

• EMEA statement on use of antiretroviral treatment in HIV-patients with hepatic impairment and/or HBV/HCV co-infection Hepatitis coinfection - Side effects - 13 September 2005

• US Preventative Services Task Force recommends screening all pregnant women for HIV PMTCT and maternal health - 13 September 2005

• Volume 6 Number 9 September 2005 PDF Other news - 1 September 2005

• Volume 6 Number 8 August 2005 Editorial - 14 August 2005

• 3rd IAS Conference on HIV Pathogenesis and Treatment, 24-27 July 2005, Rio de Janeiro, Brasil Conference reports - Conference index - 14 August 2005

• Keystone vaccine symposia 2005: vaccines, pathogenesis, snow and a couple of elk Conference reports - Vaccines and microbicides - Conference index - 14 August 2005

• HIV/HCV coinfection – part 1 Hepatitis coinfection - Special reports - 14 August 2005

• Forty injured, ten shot at peaceful protest to demand treatment in South Africa Treatment access - 14 August 2005

• FDA approve additional Indian generics Treatment access - 14 August 2005

• Medical innovation and patent gridlock Treatment access - 14 August 2005

• US adult guidelines updated – July 2005 Guidelines - 14 August 2005

• FDA filing of T-20 sNDA for administration with a needle-free injection device Antiretrovirals - 14 August 2005

• New study urges caution over widespread criminalisation of HIV transmission Other news - 14 August 2005

• Canada changes visa process for HIV-positive visitors – an example for the US? Other news - 14 August 2005

• Medscape full text articles On the web - 14 August 2005

• Volume 6 Number 8/9 August 2005 PDF PDFs - 1 August 2005

• Volume 6 Number 7 July 2005 Editorial - 15 July 2005

• 14th International HIV Drug Resistance Workshop (14th IHDRW), 7-11 June 2005, Quebec City, Canada Conference reports - Conference index - Intl Drug Resistance Workshop 14 Quebec 2005 - 15 July 2005

• Genetic factors affecting HIV infection and progression rates: immunological factors relating to entry inhibitors Basic science and immunology - Conference reports - Intl Drug Resistance Workshop 14 Quebec 2005 - 15 July 2005

• Resistance during MTCT strategies: new data on protective benefit of Combivir added to single-dose nevirapine, and impact of treatment and breastfeeding on the infant Conference reports - PMTCT and maternal health - Intl Drug Resistance Workshop 14 Quebec 2005 - 15 July 2005

• Reduced replicative capacity of M184V explains benefit of 3TC monotherapy compared to stopping all drugs Antiretrovirals - Conference reports - Intl Drug Resistance Workshop 14 Quebec 2005 - 14 July 2005

• Interaction between tenofovir and ddI in triple-nucleoside combinations: role of M184V in explaining resistance on failure Conference reports - Resistance - Intl Drug Resistance Workshop 14 Quebec 2005 - 14 July 2005

• Predicting clinical responses to ddI from genotypic resistance Conference reports - Resistance - Intl Drug Resistance Workshop 14 Quebec 2005 - 14 July 2005

• Under-detection of transmission of transmitted resistance and impact on treatment response Conference reports - Resistance - Intl Drug Resistance Workshop 14 Quebec 2005 - 14 July 2005

• Risk of death in UK after diagnosis of 3-class resistance Conference reports - Resistance - Intl Drug Resistance Workshop 14 Quebec 2005 - 14 July 2005

• Six Indian generic ARVs are given FDA tentative approval Treatment access - 14 July 2005

• Methadone and buprenorphine added to WHO list of essential medicines Treatment access - 14 July 2005

• MSF's pricing guide to purchasing ARVs: 8th edition online Treatment access - 14 July 2005

• WHO 3 by 5 progress report Treatment access - 14 July 2005

• TMC-114 to be submitted for registration based on Phase 2b trial results: expanded access expected in UK in Autumn 2005 Antiretrovirals - 14 July 2005

• Tipranavir (Aptivus) approved in US Antiretrovirals - 14 July 2005

Next page